Table 1.
Characteristics of 71 patients with vitamin D supplementation
| Total group | Supplementation by capsules | Supplementation by drops | P | |
|---|---|---|---|---|
| Subjects (females/males), n | 71 (46/25) | 52 (38/14) | 19 (16/3) | 0.5 |
| Age in years, mean (SD) | 83 (7) | 83 (7) | 82 (8) | 0.4 |
| Serum 25(OH)D1 nmol/L, mean (SD) | 77 (30) | 90 (22) | 41 (18) | <0.001 |
| Ser. 25(OH)D in residents, % (n) | ||||
| ≥75 | 61 (43) | 80 (42) | 5 (1) | |
| ≥50-74.9 | 17 (12) | 14 (7) | 26 (5) | |
| 30-49.9 nmol/L | 14 (10) | 6 (3) | 37 (7) | |
| < 30 nmol/L | 8 (6) | 0 (0) | 32 (6) | |
| Duration supplementation% (n) | <0.001 | |||
| 3-6 months | 24 (17) | 33 (17) | 0 (0) | |
| 12-18 months | 45 (32) | 60 (31) | 5 (1) | |
| >18 months | 31 (22) | 7 (4) | 95 (18) | |
| Subjects with sunlight exposure >1 × week% (n) | 61 (43) | 44 (23) | 74 (14) | 0.2 |
| Number of medications% (n) | 0.9 | |||
| <5 | 73 (52) | 73 (38) | 74 (14) | |
| >5 | 27 (19) | 27 (14) | 26 (5) | |
| Medication influencing 25(OH)D | 15 (11) | 15 (8) | 15 (3) | 0.8 |
| - anticonvulsants | 1 (1) | 2 (1) | 0 | |
| - corticosteroids | 14 (10) | 13 (7) | 15 (3) | |
| FAC2, % (n) | 0.3 | |||
| 0 | 39 (27) | 43 (23) | 21 (4) | |
| 1 | 11 (8) | 10 (5) | 16 (3) | |
| 2 | 11 (8) | 10 (5) | 16 (3) | |
| 3 | 14 (10) | 10 (5) | 26 (5) | |
| 4 | 21 (15) | 23 (12) | 16 (3) | |
| 5 | 4 (3) | 4 (2) | 5 (1) | |
| BMI3, % (n) | 0.01 | |||
| <20 underweight | 55 (39) | 60 (31) | 42 (8) | |
| 20-25 healthy weight | 34 (24) | 34 (18) | 32 (6) | |
| >25 overweight | 11 (8) | 6 (3) | 26 (5) | |
| MDRD4, % (n) | 0.7 | |||
| <60 | 31 (22) | 33 (17) | 26 (5) | |
| >60 | 69 (49) | 67 (35) | 74 (14) | |
| Chronic disease5, % (n) | 0.6 | |||
| ≤2 | 73 (52) | 73 (38) | 74 (14) | |
| >2 | 27 (19) | 27 (14) | 26 (5) |
Values are mean (SD) or number (percentage).